Variational AI

Description

Variational AI is at the forefront of early-stage drug discovery, leveraging advanced generative AI to identify and design novel, drug-like small molecules. Their proprietary Enki™ platform is engineered to generate optimized, synthesis-ready compounds that are tailored to specific target product profiles. This innovative approach aims to redefine the economics of drug discovery by significantly reducing the time and cost associated with traditional methods.

The Enki™ platform addresses the vastness of chemical space, estimated at 10⁶⁰ possible drug-like molecules, by moving beyond the limitations of conventional screening libraries. Instead of starting with known compounds, Enki™ generates entirely new molecular structures de novo. This allows R&D teams to explore uncharted chemical territories and discover first- and best-in-class compounds. The platform is purpose-built for early-stage drug discovery, covering 873 pre-trained drug targets across various key classes, including kinases, GPCRs, and proteases.

Variational AI's process begins with defining the preclinical target product profile (TPP), specifying on/off-targets and desired physico-chemical properties as input for the Enki™ AI. The platform then generates a diverse set of novel structures that meet these defined criteria. Partners can select compounds for synthesis and testing, or utilize Enki™ for hyper-efficient lead optimization, even when constrained to a specific scaffold. This multiparameter optimization capability allows for simultaneous refinement across over 50 parameters, including potency, selectivity, toxicity, ADMET properties, pharmacokinetics, and synthetic accessibility.

The company's mission is to transform early drug discovery through generative AI, driven by a cross-disciplinary team of machine learning researchers, chemists, and biotech professionals. By providing higher-quality leads and reducing costly iterations, Variational AI aims to accelerate timelines and increase the probability of success for drug development programs, ultimately benefiting patients who need new therapeutics. Their collaborations with biopharmaceutical partners span various disease areas, underscoring their commitment to positively impacting lives through scientific innovation.

Variational AI's Core Features

• Generative AI platform for drug discovery

• Enki™ platform for compound generation

• Optimizes for potency, selectivity, ADMET, and synthetic feasibility

• Generates novel, synthesis-ready, lead-like compounds

• Bypasses hit identification and hit-to-lead stages

• Enables direct move to Lead Optimization

• Covers 873 pre-trained drug targets

• Simultaneous optimization across 50+ parameters

• De novo molecular structure generation

• Hyper-efficient lead optimization capabilities

• Tailored to specific target product profiles

How to use Variational AI?

1. 1

   Define Target Product Profile: Specify on/off-targets and physico-chemical properties.

2. 2

   Enki™ Generates Compounds: The AI designs novel, diverse structures meeting the TPP.

3. 3

   Select Compounds: Choose molecules for synthesis and testing.

4. 4

   Lead Optimization: Utilize Enki™ for hyper-efficient optimization if needed.

Variational AI's Use Cases

• Novel Compound Design
• Lead Optimization
• Targeted Drug Discovery
• Exploring Chemical Space
• Therapeutic Development
• De Novo Synthesis Planning

FAQ from Variational AI

• What is Variational AI's primary focus?

  Variational AI focuses on discovering novel, drug-like small molecules for early-stage drug discovery using generative AI.

• How does the Enki™ platform work?

  Enki™ generates optimized, synthesis-ready compounds de novo, tailored to specific target product profiles, by optimizing across numerous parameters.

• What is the main benefit of using Variational AI's platform?

  The platform enables partners to bypass hit identification and hit-to-lead stages, moving directly into lead optimization with novel chemical structures.

• What types of drug targets does Enki™ cover?

  Enki™ is built for early-stage drug discovery and covers 873 pre-trained drug targets, including kinases, GPCRs, proteases, and more.

• Can Enki™ optimize existing lead compounds?

  Yes, Enki™ can perform hyper-efficient lead optimization, even when constrained to a defined scaffold.

• What parameters does Enki™ optimize simultaneously?

  Enki™ simultaneously optimizes across over 50 parameters, including potency, selectivity, toxicity, ADMET, pharmacokinetics, and synthetic accessibility.

• What is the advantage of de novo generation over traditional screening?

  De novo generation allows exploration of uncharted chemical space, moving beyond fixed screening libraries to discover unique molecular structures.

• Who are Variational AI's typical partners?

  Variational AI collaborates with biopharmaceutical partners for drug discovery programs.

• What is the goal of Variational AI's approach?

  The goal is to redefine the unit economics of drug discovery, leading to better patient outcomes by accelerating timelines and increasing success probabilities.

• What is the estimated chemical space for drug-like molecules?

  The chemical space for drug-like molecules is estimated to be unimaginably large, around 10⁶⁰.